Tafenoquine: a toxicity overview

Introduction: A century-long history in 8-aminoquinolines, the only anti-malaria drug class preventing malaria relapse, has resulted approval of tafenoquine by U.S. Food and Drug Administration (FDA) Australian Therapeutic Goods (TGA) to date registration Brazil Thailand. Tafenoquine is an alternative anti-relapse treatment for vivax prophylaxis. It should not be given pregnancy, during lactation infants with glucose-6-phosphate dehydrogenase (G6PD) unknown or deficient status, those G6PD deficiency psychiatric illness.Areas covered: This systematic review assesses associated adverse events English-language, human clinical trials. Meta-analysis commonly reported was conducted grouped comparison arms.Expert opinion: Tafenoquine, either radical cure prophylaxis, generally well tolerated adults. There no convincing evidence neurologic, ophthalmic, cardiac toxicities. Psychotic disorder which been attributed higher doses a contraindication chemoprophylaxis indication illness warning indication. Pregnancy assessment quantitative testing are required. The optimal curative regimen including dose along its safety parts Southeast Asia, South America, Oceania needs further assessment.